Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial
ConclusionsTherapeutic anticoagulation with rivaroxaban compared to prophylactic anticoagulation with a heparin did not improve surrogates of clinical outcome in patients with moderate to severe COVID-19. Whether initial rivaroxaban at therapeutic doses might be superior to thromboprophylaxis in patients with COVID-19 and a high risk as defined byd-dimer > 2 ULN needs confirmation in further studies.Graphical abstract
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
More News: Bleeding | Cardiology | Clinical Trials | COVID-19 | Heart | Heart Attack | Hemorrhagic Stroke | Stroke | Study | Thrombosis